ArticleJournal of cancer research and clinical oncology2026
Predictive value of folate receptor-positive circulating tumor cells in postoperative progressive disease of non-small cell lung cancer patients.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPostoperative recurrence and metastasis constitute critical obstacles for resected non-small cell lung cancer (NSCLC) patients, and reliable predictive biomarkers are still scarce. This study aimed to evaluate whether folate receptor-positive CTC (FR
methodWe retrospectively enrolled stage I-IIIA NSCLC patients undergoing radical resection from 2018 to 2021. Perioperative blood samples were collected for FR
resultIn total, 171 NSCLC patients were enrolled. Stage III disease had higher preoperative FR⁺CTC positivity than stage I-II (69.39% vs. 52.46%, P = 0.043). Male gender, smoke, squamous histology and stage III correlated with elevated postoperative FR⁺CTC positivity (all P < 0.05). Among 152 patients for survival analysis, 36 developed 36‑month PD. Multivariate Cox confirmed postoperative FR⁺CTC positivity (HR = 2.25, P = 0.018) and stage III (HR = 3.43, P = 0.005) as independent PD predictors. FR⁺CTC conversion from preoperative negative to postoperative positive conferred the highest PD risk and shortened PFS.
conclusionPostoperative FR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.